Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 13Recruiting 7Completed 7Terminated 2Not yet recruiting 2Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Lymphoma, Follicular 1Glioblastoma 1Astrocytoma 1

Interventions

Specimen Handling 16Biopsy 11Magnetic Resonance Spectroscopy 10Taxes 4Bevacizumab 4Cyclophosphamide 3Cetuximab 3olaparib 2decitabine and cedazuridine drug combination 2Vincristine 2Prednisone 2Paclitaxel 2Immunoglobulin G 2Gemcitabine 2Doxorubicin 2Disulfides 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2(225)Ac-DOTA-c(RGDyK) 2zimberelimab 1zanubrutinib 1trastuzumab deruxtecan 1taletrectinib 1spartalizumab 1sotigalimab 1relatlimab 1regorafenib 1prednylidene 1neratinib 1mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Radiotherapy, Intensity-Modulated × 30 days × Clear all
NCT06860594 2026-06-05

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡